Moxifloxacin Fluoroquinolone Antibacterial Pale Yellow Powder CAS 354812-41-2

Basic Information
Place of Origin: China
Brand Name: ChineseHormone
Certification: GMP, ISO 9001, USP
Model Number: CAS 354812-41-2
Minimum Order Quantity: Free samples Available
Price: negotiated
Packaging Details: as your required
Delivery Time: 3-7 working days
Payment Terms: Western Union, MoneyGram, T/T, Bitcoin
Supply Ability: 500-1000 kg / month
MW: 401.431 MF: C21H24FN3O4
Appearance: Pale Yellow Powder Biological Half-life: 12.1 Hours
Trade Names: Avelox Vigamox, Moxeza (eye Drops) Routes Of Administration: Oral, IV, Local (eyedrops)
Email: Whatsapp: 86-15871352379
Wickr: Tonyraws
High Light:

legal oral steroids


anabolic muscle building

Moxifloxacin Fluoroquinolone Antibacterial Pale Yellow Powder CAS 354812-41-2


Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand namesAvelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion.


Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiellaspecies), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria.


It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria andanaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone


Medical uses


Moxifloxacin is used to treat a number of infections, including: respiratory tract infections, cellulitis,anthrax, intraabdominal infections, endocarditis, meningitis, and tuberculosis.


The initial approval by the FDA (December 1999) encompassed these indications:


Moxifloxacin Fluoroquinolone Antibacterial Pale Yellow Powder CAS 354812-41-2 0

The European Union requires that moxifloxacin only be prescribed when other antibiotics that have been initially recommended for treatment cannot be used or have failed.


No uses within the pediatric population for oral and intravenous moxifloxacin have been approved. A significant number of drugs found within this class, including moxifloxacin, are not licensed by the FDA for use in children due to the risk of permanent injury to the musculoskeletal system.


In ophthalmology, moxifloxacin is approved for the treatment of conjunctival infections caused by susceptible bacteria.


Trade names

Avelox,Vigamox, Moxeza (eye drops)

CAS Number




Molar mass

401.431 g/mol

Biological half-life

12.1 hours



Protein binding


Routes of administration

Oral, IV, local (eyedrops)


Any needs, please contact me


Whatsapp: 86-15871352379

Wickr: tonyraws


Contact Details
Sales Manager

Phone Number : +8613657291547

WhatsApp : +